Objective: An excess of prolactin above 25ng/mL (hyperprolactinemia) can be identified in up to 10% of the population and in women is cause of infertility. The purpose of the study was to model the economic and health consequences of cabergoline, bromocriptine and the sequential therapy (ST) (defined as the treatment initiated with bromocriptine followed by cabergoline) in the management of women with hyperprolactinemia who desired to be pregnant from the health care payer's perspective. Methods: A cost-effectiveness analysis was developed using a Bayesian decision-tree model. The model simulates costs and effectiveness outcomes in a 31-months period. Effectiveness measure was the percentage of women who got pregnant during the analysis period. The comparators were cabergoline (0.5mg twice a week), bromocriptine (5mg/24hrs) and sequential therapy. Resource use and cost data were obtained from hospital records of patients (between 20-40yrs old who previously told their intention to get pregnant) being treated at a third-level hospital within the Social Security Institute for State Workers (ISSSTE) in Mexico City (n=18). Effectiveness data and model transition probabilities were obtained from international published literature. Costs and health outcomes were discounted using a 3% annual rate. The decision-tree model was calibrated according to international guidelines. One-way and probabilistic sensitivity analyses were performed using Monte Carlo Simulation first-order approach. Results: Patients who received ST experienced more effectiveness (43%) compared with patients treated with cabergoline (40%) and bromocriptine (26%). Mean costs per patient were higher with cabergoline (US$5027±500) compared with ST (US$4356±774) and bromocriptine (US$3955±769). The ICERs using bromocriptine as baseline treatment, were US$2367±506 and US$7443±6,376 for ST and cabergoline, respectively. Sensitivity analyses showed that cabergoline could be a cost-saving therapy reducing its price in 18% (p<0.05). Conclusion: In Mexico, ST demonstrated to be a cost-effective strategy for the treatment of infertility associated to hyperprolactinemia in women who want to get pregnant.